The emerging role of lapatinib in HER2-positive breast cancer

Alice Ulhoa-Cintra; Larisa Greenberg; Charles E. Geyer

doi:10.1007/s11912-008-0004-0

The emerging role of lapatinib in HER2-positive breast cancer

Alice Ulhoa-Cintra, Larisa Greenberg, Charles E. Geyer

Internal Medicine

Research output: Contribution to journal › Review article › peer-review

22 Scopus citations

Abstract

In breast cancer, overexpression of HER2 is associated with an aggressive tumor phenotype and poor prognosis. Lapatinib has demonstrated benefit in combination with capecitabine in patients with HER2-positive locally advanced and metastatic breast cancer that has progressed after prior treatment with an anthracycline, a taxane, and trastuzumab. It has also demonstrated benefit with paclitaxel in patients with metastatic disease not previously treated with chemotherapy. This review discusses results from clinical trials suggesting an advantage with the use of lapatinib with other treatment modalities in the setting of metastatic and locally advanced disease.

Original language	English (US)
Pages (from-to)	10-17
Number of pages	8
Journal	Current oncology reports
Volume	10
Issue number	1
DOIs	https://doi.org/10.1007/s11912-008-0004-0
State	Published - Jan 1 2008

ASJC Scopus subject areas

Oncology

Access to Document

10.1007/s11912-008-0004-0

Cite this

@article{49a8ebd0296f4940b1c7e752fffb2079,

title = "The emerging role of lapatinib in HER2-positive breast cancer",

abstract = "In breast cancer, overexpression of HER2 is associated with an aggressive tumor phenotype and poor prognosis. Lapatinib has demonstrated benefit in combination with capecitabine in patients with HER2-positive locally advanced and metastatic breast cancer that has progressed after prior treatment with an anthracycline, a taxane, and trastuzumab. It has also demonstrated benefit with paclitaxel in patients with metastatic disease not previously treated with chemotherapy. This review discusses results from clinical trials suggesting an advantage with the use of lapatinib with other treatment modalities in the setting of metastatic and locally advanced disease.",

author = "Alice Ulhoa-Cintra and Larisa Greenberg and Geyer, {Charles E.}",

year = "2008",

month = jan,

day = "1",

doi = "10.1007/s11912-008-0004-0",

language = "English (US)",

volume = "10",

pages = "10--17",

journal = "Current Oncology Reports",

issn = "1523-3790",

publisher = "Current Science, Inc.",

number = "1",

}

TY - JOUR

T1 - The emerging role of lapatinib in HER2-positive breast cancer

AU - Ulhoa-Cintra, Alice

AU - Greenberg, Larisa

AU - Geyer, Charles E.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - In breast cancer, overexpression of HER2 is associated with an aggressive tumor phenotype and poor prognosis. Lapatinib has demonstrated benefit in combination with capecitabine in patients with HER2-positive locally advanced and metastatic breast cancer that has progressed after prior treatment with an anthracycline, a taxane, and trastuzumab. It has also demonstrated benefit with paclitaxel in patients with metastatic disease not previously treated with chemotherapy. This review discusses results from clinical trials suggesting an advantage with the use of lapatinib with other treatment modalities in the setting of metastatic and locally advanced disease.

AB - In breast cancer, overexpression of HER2 is associated with an aggressive tumor phenotype and poor prognosis. Lapatinib has demonstrated benefit in combination with capecitabine in patients with HER2-positive locally advanced and metastatic breast cancer that has progressed after prior treatment with an anthracycline, a taxane, and trastuzumab. It has also demonstrated benefit with paclitaxel in patients with metastatic disease not previously treated with chemotherapy. This review discusses results from clinical trials suggesting an advantage with the use of lapatinib with other treatment modalities in the setting of metastatic and locally advanced disease.

UR - http://www.scopus.com/inward/record.url?scp=38149058790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38149058790&partnerID=8YFLogxK

U2 - 10.1007/s11912-008-0004-0

DO - 10.1007/s11912-008-0004-0

M3 - Review article

C2 - 18366956

AN - SCOPUS:38149058790

SN - 1523-3790

VL - 10

SP - 10

EP - 17

JO - Current Oncology Reports

JF - Current Oncology Reports

IS - 1

ER -

The emerging role of lapatinib in HER2-positive breast cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this